Rhenium-188P2045 is under clinical development by Andarix Pharmaceuticals and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Rhenium-188P2045’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rhenium-188P2045 overview

Rhenium-188P2045 is under development for the treatment of SSTR expressing squamous non-small cell lung carcinoma, small cell lung cancer and pancreatic cancer. It is administered as an intravenous infusion. The drug candidate is a radiopharmaceutical that combines a high-affinity somatostatin receptor-binding peptide with the high-energy, beta-emitting radionuclide Rhenium-188. It specifically targets tumors that over-express somatostatin receptors (SSTR). It was also under development for neuroendocrine tumors. The drug candidate is developed based on peptide targeted radionuclide technology.

Andarix Pharmaceuticals overview

Andarix Pharmaceuticals develops and commercializes novel therapies to treat cancer. The company is investigating its lead product candidate Tozaride (Rhenium 188 P2045), that combines somatostatin receptor-binding peptide to treat small and non-small cell lung, neuroendocrine and other cancers. It also develops companion diagnostic agents based on Technitium Tc99 imaging isotope. The company utilizes its proprietary peptide targeted radionuclide technology to image and kill cancer cells. Andarix Pharmaceuticals is headquartered in Somerville, Massachusetts, the US.

For a complete picture of Rhenium-188P2045’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.